Immuno-Oncology
Expert guidance in immuno-oncology discovery and development, leveraging the latest scientific knowledge in cancer immunotherapy.
Key Capabilities
- Checkpoint inhibitor program strategy and development
- CAR-T and adoptive cell therapy consulting
- Tumor microenvironment analysis and biomarker strategy
- Combination immunotherapy program design
- Oncolytic virus development and gene editing strategies
- Preclinical IO model selection and study design
- Regulatory strategy for IO biologics
Our Approach
Immuno-oncology has transformed cancer treatment, and Bionavigen is at the forefront of this revolution. Our consultants bring deep expertise in the mechanisms of anti-tumor immunity and the development of therapies that harness the immune system.
We provide strategic guidance on all aspects of IO drug development, from early target validation through clinical proof-of-concept. Our experience spans checkpoint inhibitors, cell therapies, oncolytic viruses, and combination approaches.
Bionavigen helps clients navigate the complex biology of the tumor microenvironment and design studies that generate compelling clinical data to support regulatory approval.